Literature DB >> 9425280

Calmodulin-dependent protein kinase IV during T-cell development.

J Krebs1, A Wilson, P Kisielow.   

Abstract

In a primary cell culture system of fetal rat brain, the calmodulin-dependent protein-kinase IV (CaMKIV) could be induced by the thyroid hormone T3 in a time- and concentration-dependent manner, provided the tissue was excised not later than day 15 of gestation (E15) (Krebs et al., J. Biol. Chem. 271, 11055, 1996). We report here that in the fetal thymus CaMKIV could not be detected earlier than day 16 of gestation and that the expression of this enzyme was fully upregulated at day 18. In mouse fetal thymus organ culture (FTOC) of day 14 embryonic thymus, CaMKIV could not be detected, even after several days of culture if a minimal culture medium lacking fetal calf serum was used. However, after addition of fetal calf serum to the culture medium the expression of CaMKIV could be specifically induced. Furthermore, it could also be shown that during T-cell development in the adult murine thymus the expression of CaMKIV was tightly regulated. Taken together, these results demonstrate that the expression of CaMKIV, an enzyme involved in the regulation of Ca(2+)-dependent gene expression, is itself under stringent regulatory control during tissue development.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9425280     DOI: 10.1006/bbrc.1997.7823

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Calcium/calmodulin-dependent protein kinase IV (CaMKIV) activation contributes to the pathogenesis of experimental colitis via inhibition of intestinal epithelial cell proliferation.

Authors:  Kellie E Cunningham; Elizabeth A Novak; Garret Vincent; Vei Shaun Siow; Brian D Griffith; Sarangarajan Ranganathan; Matthew R Rosengart; Jon D Piganelli; Kevin P Mollen
Journal:  FASEB J       Date:  2018-08-16       Impact factor: 5.191

2.  Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV.

Authors:  Yuang-Taung Juang; Ying Wang; Elena E Solomou; Yansong Li; Christian Mawrin; Klaus Tenbrock; Vasileios C Kyttaris; George C Tsokos
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

Review 3.  Variability in the immune system: of vaccine responses and immune states.

Authors:  Shai S Shen-Orr; David Furman
Journal:  Curr Opin Immunol       Date:  2013-08-13       Impact factor: 7.486

Review 4.  Systems vaccinology: its promise and challenge for HIV vaccine development.

Authors:  Helder I Nakaya; Bali Pulendran
Journal:  Curr Opin HIV AIDS       Date:  2012-01       Impact factor: 4.283

5.  Calcium/Calmodulin-Dependent Protein Kinase IV (CaMKIV) Mediates Acute Skeletal Muscle Inflammatory Response.

Authors:  DanDan Shi; RuiCai Gu; YaFeng Song; MaoChao Ding; Tao Huang; MengXia Guo; JiangWei Xiao; WenHua Huang; Hua Liao
Journal:  Inflammation       Date:  2018-02       Impact factor: 4.092

Review 6.  The Calcium/Calmodulin-Dependent Kinases II and IV as Therapeutic Targets in Neurodegenerative and Neuropsychiatric Disorders.

Authors:  Kinga Sałaciak; Aleksandra Koszałka; Elżbieta Żmudzka; Karolina Pytka
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

7.  Systems biology of vaccination for seasonal influenza in humans.

Authors:  Helder I Nakaya; Jens Wrammert; Eva K Lee; Luigi Racioppi; Stephanie Marie-Kunze; W Nicholas Haining; Anthony R Means; Sudhir P Kasturi; Nooruddin Khan; Gui-Mei Li; Megan McCausland; Vibhu Kanchan; Kenneth E Kokko; Shuzhao Li; Rivka Elbein; Aneesh K Mehta; Alan Aderem; Kanta Subbarao; Rafi Ahmed; Bali Pulendran
Journal:  Nat Immunol       Date:  2011-07-10       Impact factor: 25.606

8.  Gli3 in fetal thymic epithelial cells promotes thymocyte positive selection and differentiation by repression of Shh.

Authors:  Anisha Solanki; Diana C Yanez; Susan Ross; Ching-In Lau; Eleftheria Papaioannou; Jiawei Li; José Ignacio Saldaña; Tessa Crompton
Journal:  Development       Date:  2018-01-31       Impact factor: 6.862

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.